Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioHarvest Sciences ( (BHST) ) is now available.
BioHarvest Sciences said on May 12, 2026 that its CDMO division has signed a US$1.2 million Stage 2 contract in a multi-stage program to develop a rare scent-producing plant for the global fragrance industry, following completion of Stage 1 in March 2026. The source plant’s raw material is among the world’s most valuable fragrances, with demand growing in the Middle East, Asia and luxury Western markets, and Stage 2 is expected to yield enough material for commercial trials within six to nine months.
Under the agreement, BioHarvest retains 20% ownership of the compositions developed and will also act as manufacturer, positioning the company for a long-term, royalty-based revenue stream as the cell bank advances toward commercialization. Management said the contract, signed with a prominent UAE-based investment group aiming for commercialization in the second half of 2027, underscores that the key technological hurdle has been cleared and could catalyze additional fragrance programs, supporting BioHarvest’s push into the US$23 billion premium fragrance segment of the wider scents and fragrances market.
The most recent analyst rating on (BHST) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial quality (ongoing losses and sustained cash burn) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by a constructive earnings-call outlook featuring strong growth, margin improvement, a much stronger cash position, and 2026 profitability/revenue acceleration targets.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a botanical synthesis company that develops plant-based compounds without growing the underlying plants, operating both as a contract development and manufacturing organization and as a producer of proprietary nutraceutical health and wellness products, including dietary supplements. The Vancouver- and Rehovot-based firm targets customers seeking novel, science-based plant-derived molecules and participates in global fragrance and therapeutic markets through its patented technology platform.
Average Trading Volume: 27,776
Technical Sentiment Signal: Buy
Current Market Cap: $89.99M
See more data about BHST stock on TipRanks’ Stock Analysis page.